Jefferies (NYSE:JEF) analyst David Steinberg maintained a Buy rating on Supernus Pharmaceuticals (NASDAQ:SUPN) on Sunday, setting a price target of $44, which is approximately 47.95% above the present share price of $29.74.
Steinberg expects Supernus Pharmaceuticals to post earnings per share (EPS) of $0.41 for the fourth quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Supernus Pharmaceuticals, with an average price target of $40.5.
The analysts price targets range from a high of $44 to a low of $37.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $148.46 million and a net profit of $32.68 million. The company's market cap is $1.53 billion.
According to TipRanks.com, Jefferies analyst David Steinberg is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.2% and a 48.70% success rate.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.